688331 RemeGen Co., Ltd.
- 51.91
- -0.68-1.29%
RemeGen Co., Ltd. News
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
RemeGen Celebrates World Lupus Day 2024 With Increased Lupus Visibility Through Vital Knowledge Sharing
The biotech company continues to offer hope to systemic lupus erythematosus (SLE) patients globally by sharing the latest developments of its proprietary novel fusion protein drug Telitacicept YANTAI
Rongchang Biology (688331): R&D continues to progress smoothly in the research pipeline
The company released the 2023 annual report and the 2024 quarterly report: total revenue in 2023 was 1,083 billion yuan, up 40.26% year on year; net profit to mother - 1,511 billion yuan. Revenue growth was mainly due to injectable tetracycline
Express News | Rongchang Biotech rose more than 6%, and institutions are bullish on its target price to HK$56
Changes in Hong Kong stocks 丨 Rongchang Biotech rose more than 6%, institutions are bullish on its target price to HK$56
Glonghui, May 8 | Rongchang Biotech (9995.HK) rose more than 6% to HK$32.1, with a total market value of HK$17.5 billion. According to the latest report by BOC International, while maintaining Rongchang Biotech's “buy” rating, the target price is HK$56, an increase of about 75% from the current price. As of 1Q24, the cash on the company's account reached 620 million yuan. Currently, there is still a bank credit line of 4 billion yuan, and additional A-share issuance is already on the schedule. The bank expects that subsequent capital injections will be sufficient to guarantee the company's operations to break-even. The company has many catalysts in product commercialization, clinical data reading, mainland supervision and approval, and overseas travel in 2024
Changes in Hong Kong stocks | Rongchang Biotech (09995) rose more than 5%, strong product sales in the first quarter, and an important catalyst is about to land
Rongchang Biotech (09995) rose more than 5%. As of press release, it rose 5.43% to HK$32.05, with a turnover of HK$24.2386 million.
BOC International: Maintaining Rongchang Biotech's (09995.HK) “Buy” Rating Target Price of HK$56
BOC International released a research report stating that it maintains Rongchang Biotech's (09995.HK) “buy” rating, with a target price of HK$56. The bank kept the company's profit forecast unchanged: revenue for 2024-26 reached 1.66 billion/2.50 billion/3.73 billion yuan respectively, net loss gradually narrowed, and break-even was achieved in 2027. The company has many catalysts in product commercialization, clinical data reading, mainland supervision and approval, and overseas travel in 2024.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Rongchang Biotech (9995.HK): Strong sales of 1Q24 products and loss reduction, important catalysts will soon be concentrated on implementation to maintain purchases
1Q24 product sales continued to rise, with month-on-month fee cuts and losses: according to A shares (688331 CH) disclosure, the company recorded revenue of 330 million yuan (RMB, same below), a year-on-year increase of 96.4%, a year-on-year increase of 96.4%, compared to the previous month.
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 26%, leading the innovative drug concept, ASCO catalyzes market conditions, institutions are optimistic about policy+health insurance marginal improvement
Zhitong Finance App learned that innovative drug concept stocks showed strong performance. As of press release, Cornerstone Pharmaceutical-B (02616) rose 26.14% to HK$1.11; Cansino Biotech (06185) rose 16.91% to HK$20.95; Gacos-B (01167) rose 14.2% to HK$1.93; Nuocheng Jianhua (09969) rose 12.31% to HK$5.2; Rongchang Biotech (09995) rose 10.2% to HK$30.8. According to the news, the research title of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was on April 25
The Hang Seng Index rose more than 2%, the Hang Seng Technology Index rose 3.7%, Hong Kong biotech stocks rose higher, Cansino Biotech rose more than 10%, and Rongchang Biotech rose more than 6%.
The Hang Seng Index rose more than 2%, the Hang Seng Technology Index rose 3.7%, Hong Kong biotech stocks rose higher, Cansino Biotech rose more than 10%, and Rongchang Biotech rose more than 6%.
Rongchang Biology (688331): Commercialization promotion, good clinical pipeline progressing in an orderly manner
Revenue of $1,083 billion (+40.26%) was achieved in 2023; net loss to mother was $1,511 million, up slightly year-on-year loss; net loss of $1,543 million was deducted. Revenue growth was mainly due to Tetasepam and Vitacil
Changes in Hong Kong stocks | Rongchang Biotech (09995) fell more than 7%, and the loss in the first quarter increased to 349 million yuan year-on-year, and previously announced a planned increase of 2.55 billion yuan
Rongchang Biotech (09995) fell by more than 7%. As of press release, it was down 7.54% to HK$28.2, with a turnover of HK$483.39 million.
Rongchang Biotech (9995.HK): 1Q24 net loss is in line with expectations; the company maintains 2024 revenue guidance
The 1Q24 net loss was in line with expectations. The company maintains its 2024 revenue guidance. We maintain a “hold” rating and target price of HK$33. In the absence of clear guidelines on the prospects for products to go overseas, we believe that the current stock price is reasonably estimated
Rongchang Biotech (9995.HK): Overseas pipeline promotion and authorization of a new star that is deeply involved in self-avoidance+cancer BIOPHARMA can be anticipated
Taytacip: Using lupus erythematosus as a starting point to create a major FIC free product. Tetacept is the first domestically produced biologic approved to treat systemic lupus erythematosus (SLE). Judging from non-head-to-head comparisons of registered clinical trials, SLE has been approved worldwide
榮昌生物：2024年第一季度報告
Rongchang Biotech (688331.SH) announced first-quarter results with a net loss of 349 million yuan
Rongchang Biotech (688331.SH) disclosed its report for the first quarter of 2024. The company achieved operating income during the reporting period...
榮昌生物：2023 年度報告
Changes in Hong Kong stocks | Innovative drug concept stocks rose higher, Keji Pharmaceutical-B (02171) rose more than 11%, and innovative drugs ushered in a full-process support mechanism
Innovative drug concept stocks continued to rise. As of press release, Keji Pharmaceutical-B (02171) rose 10.3% to HK$5.57; Laikai Pharmaceutical-B (02105) rose 9.15% to HK$6.44; and Rongchang Biotech (09995) rose 6.29% to HK$31.25.
Changes in Hong Kong stocks | Rongchang Biotech (09995) rose more than 4%, and the company plans to increase nearly 2.6 billion yuan. The agency says there are many catalysts this year
Rongchang Biotech (09995) rose more than 4%. As of press release, it rose 4.76% to HK$29.7, with a turnover of HK$126.792 million.
Analysis
Price Target
No Data
